Article

Pharmacies Sometimes Dispense Discontinued Medications

Author(s):

MD Magazine® Staff

When physicians do not inform pharmacies that a patient's medication has been discontinued, potentially harmful medication errors can result.

When physicians do not inform pharmacies that a patient’s medication has been discontinued, potentially harmful medication errors can result.

Click here to view this article.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
Related Content
Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis
October 26th 2024

Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis

Tim Smith
Impact of CSU on Patient Quality of Life
October 25th 2024

Impact of CSU on Patient Quality of Life

David Khan, MD Kristin Sokol, MD Vivian Hernandez-Trujillo, MD Priya Bansal, MD
F. Perry Wilson, MD | Credit: Yale Medicine
October 25th 2024

KAT-AKI: Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients

Patrick Campbell
Overview of CSU: Prevalence and Presentations
October 25th 2024

Overview of CSU: Prevalence and Presentations

David Khan, MD Kristin Sokol, MD Vivian Hernandez-Trujillo, MD Priya Bansal, MD
New Phase 3b Findings Suggest Lebrikizumab Improved Skin, Itch for Atopic Dermatitis
October 25th 2024

New Phase 3b Findings Suggest Lebrikizumab Improved Skin, Itch for Atopic Dermatitis

Tim Smith
Will Herrington, MA, MBBS, MD, FRCP, FERA, Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group, Nuffield Department of Population Health, and practicing Honorary Consultant Nephrologist, Oxford Kidney Unit, Oxford University
October 25th 2024

Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.